F8 and hemophilia A: The most substantial decrease in the number of ABR and JABR events, as well as the number of hospitalisations due to bleeding and their duration, occurred at the end of the observed period when the number of patients with severe haemophilia A treated with recombinant FVIII-EHL increased by 65%.